Drugs by Numbers: Reaction‐Driven De Novo Design of Potent and Selective Anticancer Leads
- 20 November 2012
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 52 (17) , 4676-4681
Abstract
A potent and selective inhibitor of the anticancer target Polo-like kinase 1 was found by computer-based molecular design. This type II kinase inhibitor was synthesized as suggested by the design software DOGS and exhibited significant antiproliferative effects against HeLa cells without affecting nontransformed cells. The study provides a proof-of-concept for reaction-based de novo design as a leading tool for drug discovery.Keywords
This publication has 37 references indexed in Scilit:
- DOGS: Reaction-Driven de novo Design of Bioactive CompoundsPLOS Computational Biology, 2012
- Quantifying the chemical beauty of drugsNature Chemistry, 2012
- Drug discovery in the next decade: innovation needed ASAPDrug Discovery Today, 2011
- PLK1 as an oncology target: current status and future potentialDrug Discovery Today, 2011
- Neighborhood Behavior of in Silico Structural Spaces with Respect to in Vitro Activity Spaces−A Novel Understanding of the Molecular Similarity Principle in the Context of Multiple Receptor Binding ProfilesJournal of Chemical Information and Computer Sciences, 2003
- The Protein Data BankNucleic Acids Research, 2000
- Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. CohenJournal of Molecular Biology, 1997
- Prozac (fluoxetine, lilly 110140), the first selective serotonin uptake inhibitor and an antidepressant drug: Twenty years since its first publicationLife Sciences, 1995
- Molecular recognition of receptor sites using a genetic algorithm with a description of desolvationJournal of Molecular Biology, 1995
- A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-Trifluoromethylphenoxy)-n-methyl-3-phenylpropylamineLife Sciences, 1974